Navigation Links
Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis

psing forms of MS. TYSABRI increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Patients should be monitored at regular intervals for any new or worsening signs or symptoms suggestive of PML Because of the increased risk of PML, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies. It is available in the US only through a restricted distribution program called the TOUCH Prescribing Program. According to product labeling, after two years, TYSABRI treatment led to a 67% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42% (p<0.001). TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. Changes in MRI findings often do not correlate with changes in the clinical status of patients (e.g., disability progression). The prognostic significance of the MRI findings in these studies has not been evaluated.

In the European Union, TYSABRI is indicated as a single disease-modifying therapy in highly active relapsing-remitting MS patients. Because of the increased risk of PML, it is for patients with high disease activity despite treatment with a beta-interferon or in patients with rapidly evolving severe relapsing-remitting MS.

According to product labeling in the EU, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

Serious adverse events that occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis), infections, depression and gallstones. In MS trials, the incidence and rate of other serious and common adverse events, including the overall incidence and rat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/12/2014)... United Arab Emirates (PRWEB) July 12, 2014 ... another Los Angeles basketball legend is heading to the ... scorer and six-time champion will be in the UAE ... & Fitness Weekend in support of diabetes awareness. The ... an award-winning entertainment marketing and event management company based ...
(Date:7/12/2014)... Amarillo, Texas (PRWEB) July 12, 2014 ... and Breastfeeding Made Simple as a valuable new resource ... that roughly two-thirds of American women work away from ... many sources touting the benefits of breastfeeding, but often ... continuing to nurse their babies. With its evidence-based insights, ...
(Date:7/12/2014)... Restore My Vision Today is a new ... couple boasting very impressive credentials on the field of ... as a way to help consumers do without the ... respective patients’ treatments . , In particular, ... of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... 2014 Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
(Date:7/12/2014)... 12, 2014 Ladies, it doesn't matter what ... Those who are looking for an affordable gown can ... occasion dresses) to get their dream items. Recently, the company ... length gowns . Along with that, it is also providing ... the special offer; the deadline of this promotion is July ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... of Northwestern University, is a super sleuth of potentially ... team of doctors called RADAR (Research on Adverse ... School of Medicine. They swoop in to investigate early ... Administration (FDA) takes notice. ,A new study ...
... Court on Friday announced that it has accepted a ... to review the constitutionality of a Mexico City law ... the first three months' gestation, the Los Angeles Times ... Democratic Revolution in March in the Mexico City Legislature ...
... such as Girls Aloud, Pussycat Dolls and the Sugababes have ... promoting an ideal for what a womans figure should look ... ,Researchers from the universities of Leeds and Sussex ... where all the band-members are skinny, found that watching such ...
... in Physiological and Biochemical Zoology, a fascinating new ... evolution and artificial selection, providing insight into ... fluctuations. ,Dr. James Hicks, Editor in ... collection of papers: "This exciting approach experimental ...
... good for the fairer sex, for a new study has found that ... as fast as if she has just had a grueling workout. ... a group of 35 women and found that trying on a pair ... beats per minute. ,And, this is not just a one ...
... up boozing from home. ,Based on this, ... away from their middle school children, the best place to ... by a team of researchers including principal investigator Kelli Komro ... Minnesota, Minneapolis. ,As part of the study, researchers ...
Cached Medicine News:Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 3Health News:Mexico Supreme Court Accepts Petition To Review Mexico City Law Legalizing Abortion During First Three Months' Gestation 2Health News:Research Throws Light on Adaptation of E.coli to Changing Conditions 2
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: